As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 receptor agonist experienced a decreased risk for complications but an ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behaviour or pathological gambling – not so common. But a BBC investigation has highlighted ...

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring orthopedic care.

Many are in the chase of quick fixes in weight loss, but more than often it's ineffective. Expert debunks 6 common weight loss myths.